Dataset related to article: Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Systemic inflammation is associated with increased aggressiveness of breast cancer and can contribute to decreased activity of neoadjuvant treatments. Biomarkers of systemic inflammation are easily obtained from routine blood count and are highly cost-effective, having great potential to steer cancer prognosis in clinical practice. In our study we tested the hypothesis that high values of these biomarkers might have an effect on clinical outcomes in a population of patients treated with neoadjuvant chemotherapy for breast cancer. Results of our study, together with data from the literature, hint at a possible role of inflammatory markers in the diagnostic and therapeutic algorithm of breast cancer, where specific pre-operative blood cell ratios could be used in combination with biological and clinical factors to tailor adjuvant therapy.全身性炎症与乳腺癌侵袭性增强显著相关，且可降低新辅助治疗（neoadjuvant treatment）的疗效。全身性炎症生物标志物可通过常规血常规便捷获取，且性价比极高，在临床实践中对癌症预后评估与指导具备巨大应用潜力。本研究针对接受乳腺癌新辅助化疗（neoadjuvant chemotherapy）的患者队列，验证了"此类生物标志物水平升高可对临床结局产生影响"这一假说。本研究结果结合现有文献数据，提示炎症标志物在乳腺癌的诊疗决策中具备潜在作用：特定的术前血细胞比值可与生物学及临床特征相结合，用于个体化定制辅助治疗方案。